fbpx
Search
Close this search box.

InVivo Biosystems Blog

Press Release: InVivo Biosystems Unveils New Leadership Team to Drive Next Phase of Innovation and Growth
InVivo Biosystems Announces New CEO
InVivo Biosystems Partners with BioReperia to Accelerate Cancer Drug Development
Year in Review: InVivo Biosystems 2023, Wrapped
InVivo Biosystems Secures New Investment
Zebrafish vs. Mouse Models: A New Standard in Behavioral Assays
Unraveling Rare Disease Mysteries Part II: Precise CRISPR Knock-in Zebrafish Models of STXBP1 Patient Variants for Functional Studies
Image of a Zebrafish with the title of the article
Unlocking the Mystery: How New Gene Data Sheds Light on Epilepsy
WHAM with CRISPR - re-imaging how rare disease therapeutics are developed
Whole-gene Humanized Animal Models (WHAM) with CRISPR – Re-imagining how Rare Disease therapeutics are developed
America is finally investing in Biotechnology & Biomanufacturing in a Big Way
[Patent Announcement] InVivo Biosystems has officially been issued a patent on WHAM-humanization in the nematode, C. elegans
If the New Regulation on the Dietary Supplement Industry were to pass, would your Products be Compliant?
What happens if the Dietary Supplement Listing Act of 2022 passes? What if it doesn’t?
Thaena press release
[Press Release] InVivo Biosystems and Thaena Announce Novel Metabolite Research Platform With Compelling Longevity and Healthspan Implications and Outcomes
Review: How a Small Worm is Helping Uncover the Pathogenicity of Gene Variants
A Natural Fit – Using Zebrafish to Evaluate Natural Compounds for Anti-Inflammatory Properties
Differences Between HDR vs NHEJ
The Benefits of Standardizing Zebrafish Diets
[Press Release] Lifeist Subsidiary Mikra Cellular Sciences to Launch First Product “CELLF” to Combat Brain Fog and Unlock Healthy Aging, Announces U.S. Patent Application and Pre-Clinical Study
Spotlight on InVivo Biosystems’ Zebrafish Work
InVivo Biosystems Launches New Formulation Analysis Platform to Aid Healthy-Aging Product Research and Development
FAVOR Grant
New NIH Grant awarded to InVivo Biosystems to address critical needs in precision medicine research
New NIH Grant awarded to InVivo Biosystems to address critical needs in precision medicine research using the model of C. elegans. The grant, titled “Functional
NemaMetrix Expands Business to Capitalize on In-vivo Solutions to Help Speed Testing for Critical Disease Therapeutics
CRISPR Benchmark Report Findings
Bayer and NemaMetrix present C. elegans results at Parasitic Helminths conference in Greece
How are extreme weather events, such as Hurricane Katrina, spreading heartworms and other parasitic nematodes and what are the implications of their spread?
C. elegans New Lab Checklist
Are you starting a new C. elegans lab and feeling overwhelmed with starting from scratch? We want to help make this process as smooth as
NemaMetrix raises $5 million USD funding and strengthens senior team
  Investment will be used to further develop the Company’s Precisome platform for functional analysis New investment led by Oregon Venture Fund Dr Stephen Turner
New Milestone! We can now remove over 43,000 bp from C. elegans genomic DNA!
12k, 24k, 36k…we can now precisely remove over 43k bp from C. elegans genomic DNA! Knocking out genes is a commonly used tool for biologists
Child Neurology Meeting: Bernard Sachs Award to William B. Dobyns and Precision Medicine in Epilepsy Lecture
The Child Neurology Society honored William (Bill) Dobyns for his highly impactful efforts in characterizing child neurology. In a prolific and highly influential carrier, Bill
PMWC sits down with NemaMetrix to discuss emerging technologies
In preparation for the Precision Medicine World Conference on January 20-23rd, 2019, PMWC took a moment to ask us some questions about the new and
NemaMetrix wins “Job Creation” Award at Inaugural Innovation and Talent Celebration
Thursday November 15th, 2018 – NemaMetrix wins the “Job Creation” Award at the RG Media Company’s inaugural Innovation and Talent Celebration. The event was organized
KCNQ2 Cures Summit – Patient Family Passion and Involvement
The passion to find answers is inspiring. I had the good fortune to attend the KCNQ2 Cure Summit 2018. Meeting the patient families and seeing
My last grant application to the NIH proposing experiments in C. elegans got a perfect score!
‘Those of us who have studied invertebrate model organisms throughout our careers have been nervous that NIH study sections will shut the door on our
NemaMetrix becomes the first “Most Innovative” health startup at Demo Day!
NemaMetrix Inc. is the winner of the first “Most Innovative” health startup at Demo Day organized by CBInsights.
DD News features NemaMetrix in its latest issue on Animal Models of Disease
The latest issue of Drug Discovery News (DDNews) features a special report on Animal Models of Disease, highlighting the NemaMetrix/Knudra merger and the value of
Scientists study how cancer spreads by recording a time-lapse of C. elegans
Scientists from Duke University captured the cellular break-ins in C. elegans, a transparent worm that’s often used as a model for human biology. The cellular
NemaMetrix and Knudra Transgenics announce merger
NemaMetrix and Knudra Transgenics announce merger to provide fast genotype-to-phenotype answers. The combined company will operate under NemaMetrix Inc.
NemaMetrix Inc., An American Innovation Success Story
NemaMetrix Inc. was selected as the only company representing the state of Oregon by the Science Coalition in its latest Sparking Economic Growth reports released
Knudra Transgenics
Nemametrix and Knudra Transgenics Join Forces to Expand Sales and Marketing Initiatives
Nemametrix Inc., a life sciences startup that created the innovative ScreenChip System for drug screening, mutant phenotyping, and toxicological assessment, has entered into a marketing
ScreenChip Platform Recognized by the White House
The NemaMetrix ScreenChip platform technology was recognized by the White House as one of the breakthrough life science research technologies. CEO Matt Beaudet spoke with
ONAMI logo - Oregon nanoscience and Microtechnologies Institute
NemaMetrix announces GAP funding
  NemaMetrix announces being awarded $249,000 in GAP funding from Oregon Nanoscience and Microtechnologies Institute (ONAMI) to fund “proof-of-concept” work and to fuel development towards
National Institutes of Health
NemaMetrix Announces NIH funding
NemaMetrix announces being awarded $188,000 for a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Health. The funds will be
Load More

Connect with us